ReviewJournal for immunotherapy of cancer2026
Role of solute carrier family 7 member 7 in cancer: opportunities for tumor microenvironment research.
Review in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer poses serious health risks to humans. The solute carrier (SLC) family is crucial for cancer development regulation. As a member of this family, SLC7A7 forms a heterodimer with SLC3A2 to transport cationic and neutral amino acids (AA) across the membrane, thereby maintaining cellular AA homeostasis. A recent study resolved the crystal structure of SLC7A7 and identified the key residues involved in substrate binding of SLC7A7, providing important experimental evidence for the future development of small-molecule inhibitors of SLC7A7. In addition, multiple studies have revealed the expression regulation mechanism of SLC7A7 in human, mouse, and porcine cells, providing a basis for studying the regulatory mechanism of SLC7A7 expression in cancer cells. SLC7A7 is dysregulated in multiple cancers, including bladder cancer, non-small cell lung cancer, and hepatocellular carcinoma. SLC7A7 is involved in cancer proliferation and metastasis, with a notable impact on shaping the tumor microenvironment (TME) across multiple cancer types, making it a valuable target for further investigation. In this review, we discuss recent advances in understanding the structure, expression, and regulatory mechanisms of SLC7A7, focusing on its role in cancer development and the current research limitations. Furthermore, this review emphasizes the role of SLC7A7 in promoting cancer immune escape by influencing innate and adaptive immune cells in the TME and discusses its potential mechanisms of immune cell regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.